(MENAFN- Straits Research)
Cancer Biomarker Market Size & Growth Analysis
The global cancer biomarker market size was valued at USD 38.5 billion in 2025 and is projected to grow from USD 43.43 billion in 2026 to USD 113.83 billion by 2034, registering a CAGR of 12.8% during the forecast period from 2026 to 2034. North America dominated the cancer biomarker market with a market share of 41.2% in 2025.
Cancer biomarkers are biological molecules or measurable indicators found in blood, tissue, urine, or other body fluids that provide information about the presence, progression, or response to treatment of cancer. They include genetic mutations, proteins, enzymes, and other molecular signatures used for early detection, diagnosis, prognosis, treatment selection, and monitoring therapeutic outcomes, enabling more precise and personalized cancer care.
The main drivers of growth in this market are the increasing incidence of cancer worldwide, growing research on cancer biomarkers, growing use of biomarkers in drug discovery and development and individualized treatment approaches and technical developments.
Cancer Biomarker Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 38.5 Billion
2026 Market Size: USD 43.43 Billion
2034 Projected Market Size: USD 113.83 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 12.8%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 41.2%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 14.6%
Segment Insights
By Cancer Type
Leading Segment: Breast Cancer
Market Share in 2025: 17.9%
By Application
Fastest growing segment: Personalized Medicines
CAGR: 14.1% (2026-2034)
Download a Free Sample To learn more about this report,
Cancer Biomarker Market Trends
Growing Adoption of Multi-Biomarker Testing for Precision Oncology
Multi-biomarker testing is becoming increasingly important in oncology as healthcare providers seek to evaluate several molecular characteristics from individual patient samples. Next-generation sequencing panels and multiplex assays can identify multiple genomic alterations, protein markers, and other clinically relevant characteristics within a coordinated diagnostic workflow. This approach can support more efficient patient stratification and increase the ability of clinicians to match patients with targeted therapies and clinical trials.
In June 2026, the U.S. Food and Drug Administration reported continued expansion of approved companion diagnostic indications across oncology, including tests identifying multiple molecular characteristics used to guide treatment selection.
Increasing Use of Liquid Biopsy for Non-Invasive Cancer Monitoring
Liquid biopsy is gaining importance as cancer biomarker testing expands beyond conventional tissue-based analysis. Blood-based assays that detect circulating tumor DNA and other circulating biomarkers can provide molecular information without requiring repeated invasive tissue collection. Increasing assay sensitivity and clinical validation are supporting applications in treatment selection, disease monitoring, molecular residual disease detection, and recurrence assessment, creating new opportunities for biomarker testing throughout the cancer care pathway.
In May 2026, the U.S. Food and Drug Administration authorized a circulating tumor DNA-based companion diagnostic for muscle-invasive bladder cancer, supporting the use of blood-based molecular testing in treatment-related decision-making.
Cancer Biomarker Market Dynamics
Market Drivers
Expansion of Targeted and Immunotherapy Treatments Increases Demand for Cancer Biomarker Testing
The development of targeted therapies and immunotherapies is increasing the need to identify molecular and biological characteristics that determine treatment eligibility and potential response. Biomarker testing can help physicians identify actionable alterations, characterize tumor biology, and select therapies aligned with specific patient profiles. As pharmaceutical pipelines increasingly incorporate biomarker-defined patient populations, diagnostic testing is becoming more closely connected with oncology treatment decisions.
In July 2026, the U.S. Food and Drug Administration's companion diagnostic database included numerous oncology tests linked to targeted therapies and immunotherapies, reflecting the growing integration of biomarkers into cancer treatment selection.
Market Restraints
High Cost and Limited Infrastructure Restrict Access to Advanced Biomarker Testing
Advanced biomarker analysis can require specialized sequencing instruments, laboratory facilities, reagents, bioinformatics systems, and highly trained personnel. These requirements can increase testing costs and create barriers for healthcare facilities that lack molecular diagnostic infrastructure. Unequal reimbursement policies and differences in access to specialized laboratories can further limit the availability of comprehensive biomarker testing across patient populations and geographic regions.
In January 2026, U.S. healthcare policy analysis identified differences in coverage and reimbursement for advanced genomic testing as an ongoing factor influencing access to precision oncology diagnostics.
Market Opportunities
Expansion of Molecular Residual Disease Testing Creates New Biomarker Applications
Molecular residual disease testing is creating opportunities to detect very small amounts of cancer that may remain after treatment and are not readily identifiable through conventional clinical assessment. Highly sensitive biomarker assays can provide additional information about recurrence risk and treatment response in selected cancers. As evidence supporting these applications develops, MRD testing can expand the role of cancer biomarkers from initial diagnosis and therapy selection toward ongoing disease surveillance and personalized treatment management.
In May 2026, the U.S. Food and Drug Administration authorized a circulating tumor DNA-based molecular residual disease companion diagnostic for muscle-invasive bladder cancer, supporting the clinical application of molecular biomarkers in post-treatment assessment.
Market Challenges
Biological Complexity and Inconsistent Biomarker Performance Challenge Clinical Adoption
Cancer is biologically heterogeneous, and biomarker expression can vary between patients, tumors, and disease stages. Differences in specimen quality, tumor heterogeneity, assay sensitivity, analytical platforms, and interpretation methods can affect test performance and make consistent clinical validation difficult. Developers and laboratories must demonstrate reliable analytical performance and meaningful clinical utility before biomarkers can be incorporated broadly into treatment pathways, increasing the complexity of development and implementation.
In February 2026, regulatory guidance for oncology biomarker tests continued to emphasize analytical validity, clinical validity, and appropriate performance evidence before diagnostic tests can be used to support specific treatment decisions.
Cancer Biomarker Market Segmentation
By Cancer Type
Breast Cancer Dominated the Market with 17.9% Share in 2025
The breast cancer segment accounted for the largest share of the global cancer biomarker market at 17.9% in 2025, representing a market value of USD 6.89 billion. The segment is expected to maintain steady growth during the forecast period, registering a CAGR of 13.4% from 2026 to 2034. Its dominance is driven by the high global incidence of breast cancer, increasing implementation of routine screening programs, and the widespread use of biomarker tests such as HER2, BRCA1/BRCA2, and hormone receptor biomarkers for diagnosis and treatment selection. Rising adoption of precision medicine, continuous advancements in companion diagnostics, and growing awareness of early cancer detection are further supporting the expansion of this segment across developed and emerging healthcare markets.
Request Customization to receive a tailored report.
By Application
Personalized Medicines are Projected to Register the Fastest Growth at a CAGR of 14.1%
The personalized medicines segment is projected to register the fastest growth in the global cancer biomarker market, expanding at a CAGR of 14.1% during 2026–2034. In 2025, the segment accounted for 32.6% of the market, with a value of USD 12.55 billion. Growth is being fueled by the increasing use of biomarker-guided therapies that enable physicians to select treatments based on a patient's genetic and molecular profile. The rising prevalence of cancer, expanding adoption of precision oncology, growing availability of companion diagnostic tests, and significant investments in genomic research are accelerating demand for personalized treatment strategies. In addition, the increasing number of targeted therapies approved for various cancer types is expected to further strengthen the growth of this segment throughout the forecast period.
Speak to an Analyst to discuss market opportunities.
Cancer Biomarker Regional Analysis
North America Cancer Biomarker Market Analysis
North America dominated the cancer biomarker market with a 41.2% market share, valued at USD 15.86 billion in 2025. The region benefits from advanced oncology diagnostics infrastructure, high adoption of precision medicine, significant investments in cancer research, and favorable reimbursement policies for biomarker-based testing. Rising cancer incidence, increasing use of companion diagnostics, and continuous advancements in genomic and molecular diagnostics continue to support market growth across the region.
United States Cancer Biomarker Market Insights
The United States accounted for an estimated USD 13.48 billion of the market in 2025, making it the largest contributor in North America. Growth is driven by increasing adoption of next-generation sequencing, expanding precision oncology programs, strong research funding, and the presence of leading biotechnology and diagnostic companies focused on cancer biomarker development.
Canada Cancer Biomarker Market Insights
Canada generated an estimated USD 2.38 billion in 2025. Rising government healthcare expenditure, increasing investments in cancer research, expanding molecular diagnostic capabilities, and growing adoption of personalized medicine are contributing to market growth across the country.
Europe Cancer Biomarker Market Analysis
Europe accounted for 27.4% of the cancer biomarker market, reaching USD 10.55 billion in 2025. The market is supported by strong public healthcare systems, increasing implementation of precision medicine initiatives, expanding cancer screening programs, and continuous investments in biomarker research. Favorable regulatory frameworks and collaboration between research institutions and biotechnology companies continue to strengthen regional market growth.
United Kingdom Cancer Biomarker Market Insights
The United Kingdom represented an estimated USD 2.11 billion in 2025. The country's market is driven by NHS investments in precision oncology, increasing adoption of genomic testing, expanding cancer screening initiatives, and growing demand for personalized treatment approaches.
Germany Cancer Biomarker Market Insights
Germany led the European market with an estimated value of USD 2.95 billion in 2025. The country's advanced healthcare infrastructure, strong biotechnology sector, increasing investment in molecular diagnostics, and widespread adoption of companion diagnostic technologies continue to support market expansion.
Asia Pacific Cancer Biomarker Market Analysis
Asia Pacific accounted for 22.1% of the cancer biomarker market, valued at USD 8.51 billion in 2025, and is projected to register the fastest CAGR of 14.6% during the forecast period. Rising healthcare expenditure, expanding oncology care infrastructure, increasing awareness of early cancer detection, and growing investments in precision medicine are accelerating market growth across the region.
Japan Cancer Biomarker Market Insights
Japan generated an estimated USD 1.53 billion in 2025. The country's aging population, high cancer prevalence, advanced diagnostic infrastructure, and increasing adoption of genomic testing continue to fuel demand for cancer biomarker technologies.
China Cancer Biomarker Market Insights
China accounted for an estimated USD 3.57 billion in 2025, making it the largest market in the Asia Pacific. Government healthcare reforms, expanding cancer screening programs, increasing domestic biotechnology innovation, and rising investments in precision oncology are driving strong market growth.
Latin America Cancer Biomarker Market Analysis
Latin America accounted for 5.4% of the cancer biomarker market, reaching USD 2.08 billion in 2025. Increasing healthcare expenditure, improving access to advanced diagnostic technologies, growing cancer awareness, and expanding laboratory infrastructure are supporting regional market growth.
Brazil Cancer Biomarker Market Insights
Brazil accounted for an estimated USD 1.12 billion in 2025, making it the largest market in Latin America. Rising cancer incidence, expanding molecular diagnostic services, increasing public and private healthcare investments, and growing adoption of biomarker-based testing continue to drive market expansion.
Middle East & Africa Cancer Biomarker Market Analysis
The Middle East & Africa represented 3.9% of the cancer biomarker market, totaling USD 1.50 billion in 2025. Increasing investments in healthcare infrastructure, growing awareness of early cancer diagnosis, expanding oncology centers, and improving access to advanced diagnostic technologies are supporting regional market growth.
UAE Cancer Biomarker Market Insights
The United Arab Emirates (UAE) accounted for an estimated USD 0.36 billion in 2025. The country's market is driven by government investments in healthcare modernization, expanding precision medicine initiatives, increasing adoption of molecular diagnostics, and growing demand for advanced oncology testing.
Africa Cancer Biomarker Market Insights
Africa is witnessing steady growth in the cancer biomarker market, supported by expanding oncology care infrastructure, increasing cancer awareness programs, improving laboratory capabilities, and rising investments in precision diagnostics. Countries such as South Africa, Egypt, Kenya, and Nigeria are strengthening cancer diagnostic services, creating long-term growth opportunities for cancer biomarker manufacturers.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Cancer Biomarker Market Analysis
Europe accounted for 27.4% of the cancer biomarker market, reaching USD 10.55 billion in 2025. The market is supported by strong public healthcare systems, increasing implementation of precision medicine initiatives, expanding cancer screening programs, and continuous investments in biomarker research. Favorable regulatory frameworks and collaboration between research institutions and biotechnology companies continue to strengthen regional market growth.
United Kingdom Cancer Biomarker Market Insights
The United Kingdom represented an estimated USD 2.11 billion in 2025. The country's market is driven by NHS investments in precision oncology, increasing adoption of genomic testing, expanding cancer screening initiatives, and growing demand for personalized treatment approaches.
Germany Cancer Biomarker Market Insights
Germany led the European market with an estimated value of USD 2.95 billion in 2025. The country's advanced healthcare infrastructure, strong biotechnology sector, increasing investment in molecular diagnostics, and widespread adoption of companion diagnostic technologies continue to support market expansion.
Asia Pacific Cancer Biomarker Market Analysis
Asia Pacific accounted for 22.1% of the cancer biomarker market, valued at USD 8.51 billion in 2025, and is projected to register the fastest CAGR of 14.6% during the forecast period. Rising healthcare expenditure, expanding oncology care infrastructure, increasing awareness of early cancer detection, and growing investments in precision medicine are accelerating market growth across the region.
Japan Cancer Biomarker Market Insights
Japan generated an estimated USD 1.53 billion in 2025. The country's aging population, high cancer prevalence, advanced diagnostic infrastructure, and increasing adoption of genomic testing continue to fuel demand for cancer biomarker technologies.
China Cancer Biomarker Market Insights
China accounted for an estimated USD 3.57 billion in 2025, making it the largest market in the Asia Pacific. Government healthcare reforms, expanding cancer screening programs, increasing domestic biotechnology innovation, and rising investments in precision oncology are driving strong market growth.
Latin America Cancer Biomarker Market Analysis
Latin America accounted for 5.4% of the cancer biomarker market, reaching USD 2.08 billion in 2025. Increasing healthcare expenditure, improving access to advanced diagnostic technologies, growing cancer awareness, and expanding laboratory infrastructure are supporting regional market growth.
Brazil Cancer Biomarker Market Insights
Brazil accounted for an estimated USD 1.12 billion in 2025, making it the largest market in Latin America. Rising cancer incidence, expanding molecular diagnostic services, increasing public and private healthcare investments, and growing adoption of biomarker-based testing continue to drive market expansion.
Middle East & Africa Cancer Biomarker Market Analysis
The Middle East & Africa represented 3.9% of the cancer biomarker market, totaling USD 1.50 billion in 2025. Increasing investments in healthcare infrastructure, growing awareness of early cancer diagnosis, expanding oncology centers, and improving access to advanced diagnostic technologies are supporting regional market growth.
UAE Cancer Biomarker Market Insights
The United Arab Emirates (UAE) accounted for an estimated USD 0.36 billion in 2025. The country's market is driven by government investments in healthcare modernization, expanding precision medicine initiatives, increasing adoption of molecular diagnostics, and growing demand for advanced oncology testing.
Africa Cancer Biomarker Market Insights
Africa is witnessing steady growth in the cancer biomarker market, supported by expanding oncology care infrastructure, increasing cancer awareness programs, improving laboratory capabilities, and rising investments in precision diagnostics. Countries such as South Africa, Egypt, Kenya, and Nigeria are strengthening cancer diagnostic services, creating long-term growth opportunities for cancer biomarker manufacturers.
List of Key and Emerging Players in Cancer Biomarker Market
Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Illumina, Inc.
QIAGEN N.V.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
bioMérieux SA
Becton, Dickinson and Company (BD)
Myriad Genetics, Inc.
Key Industry Developments
March 2026: Roche expanded its cancer diagnostics portfolio with advanced biomarker testing solutions, including next-generation sequencing and companion diagnostics technologies designed to support precision oncology and targeted cancer therapies.
January 2026: Thermo Fisher Scientific expanded its oncology diagnostics portfolio with enhanced biomarker analysis platforms, supporting genomic profiling, liquid biopsy research, and personalized cancer treatment decisions.
October 2025: Illumina expanded its oncology sequencing solutions portfolio with advanced genomic analysis technologies designed to identify cancer biomarkers and support precision medicine applications.
August 2025: Guardant Health expanded its liquid biopsy and cancer biomarker testing portfolio with improved blood-based genomic profiling solutions designed to support early cancer detection, treatment selection, and monitoring.
Report Scope
Comments
No comment